Li Xi, Secretary of the Provincial Committee, inspects Lizhu

Time Posted：2019-02-19 14:22

On the morning of February 13, Li Xi, member of the Political Bureau of the CPC Central Committee and Secretary of the Guangdong Provincial Committee of the CPC, conducted a field research in Zhuhai to study and implement General Secretary Xi Jinping's important speeches and instructions on Guangdong, thoroughly implement the work deployment of the 6th Plenary Session of the 12th Guangdong Provincial Committee, and promote the construction of the Guangdong-Hong Kong-Macao Greater Bay Area. He engaged in in-depth exchanges with enterprise leaders and R&D personnel. Li Zhu was a key stop in Secretary Li Xi's Zhuhai inspection. Zhu Baoguo, Chairman of Li Zhu Group, and Tang Yanggang, President of Li Zhu Group, welcomed the provincial leaders to Li Zhu for inspection and research. At the Li Zhu exhibition hall, Li Zhu traditional Chinese medicine specimen museum, and Li Zhu Research Institute, Chairman Zhu Baoguo briefed Secretary Li Xi on Li Zhu's current business operations, R&D innovation achievements, and the effectiveness of its talent strategy combining local cultivation with external introduction. Secretary Li Xi exchanged views with overseas experts and scientists who grew up at Li Zhu in the company's laboratory, praising their courageous spirit of R&D innovation. During the Li Zhu research, Secretary Li Xi listened to Chairman Zhu Baoguo's introduction of the company while inquiring about issues of concern. He affirmed Li Zhu's R&D innovation achievements and business development achievements, encouraging Li Zhu to fully leverage its leading role in independent innovation, focus on overcoming key core technologies, continuously improve its core competitiveness, cultivate and introduce talents, and achieve breakthrough results in the biopharmaceutical field as soon as possible. Secretary Li Xi hopes that party committees and governments at all levels will increase their efforts to care for and support the development and growth of private enterprises, effectively help solve the difficulties encountered in their development, and help enterprises develop rapidly. Accompanying Secretary Li Xi on his inspection of Li Zhu were Zheng Yanxiong, member of the Standing Committee of the Provincial Committee and Secretary-General of the Provincial Committee; Guo Yonghang, Secretary of the Zhuhai Municipal Committee; Yao Yisheng, Mayor of Zhuhai; and Yang Huabing, Secretary of the Jinwan District Committee of Zhuhai.

A tuberculosis drug from a subsidiary of Healthy Yuan has been included in the WHO's recommended procurement list.

Time Posted：2019-02-19 14:12

On February 14, Jiankangyuan announced that its subsidiary, Lizhu Pharmaceutical Group Co., Ltd.'s wholly-owned subsidiary, Lizhu Pharmaceutical Factory, independently developed Kanamycin Injection, which passed the World Health Organization (WHO) PQ certification (prequalification), and was included in the WHO's recommended procurement list. This news was also released through an announcement by Lizhu Group. Kanamycin Injection, used in combination with other anti-tuberculosis drugs, is mainly used to treat various forms of tuberculosis caused by Mycobacterium tuberculosis. As of February 14, 2019, Lizhu Pharmaceutical Factory had invested approximately RMB 6.38 million in R&D for Kanamycin Injection. In 2017, the global sales of Kanamycin preparations totaled US\$61.151 million, an increase of 38.44% compared to 2016. Among them, the sales of Kanamycin Injection totaled US\$3.2426 million, an increase of 24.72% compared to 2016. Jiankangyuan and Lizhu Group stated that the WHO PQ certification of Kanamycin Injection has opened up channels for the international market sales of Kanamycin preparations, provided strong support for the company's further expansion into overseas markets, and laid a solid foundation for the international certification of subsequent high-end preparation products. Source: Beijing News

Exploring New Paths in "Greater Health": Healthy Element and Micro-Kang Biology Establish a Joint Research Center for Probiotics

Time Posted：2019-01-21 14:30

On January 18, 2019, a press conference for the establishment of a joint research center for probiotics was grandly held in Shenzhen by Joincare Pharmaceutical Group Industry Co., Ltd. and Jiangsu Weikang Biotechnology Co., Ltd. Leaders and numerous experts and scholars from Joincare Pharmaceutical Group Industry Co., Ltd., Jiangsu Weikang Biotechnology Co., Ltd., and Huazhong University of Science and Technology attended the press conference and witnessed this important moment.

Lizhu Group wins first prize in Zhuhai's "Party Building Leading, Second Entrepreneurship" competition

Time Posted：2019-01-16 14:50

At the turn of the old and new year, Lizhu's Party building has achieved another success, following the recent award of the "Strong Party Building, Strong Development" double-strong enterprise title. On December 27, at the "Party Building Leading, Second Entrepreneurship" competition hosted by the Zhuhai Municipal Committee Organization Department, the Zhuhai "Two New" Organization Party Working Committee, and the Zhuhai Xiangzhou District Committee and District Government, the research and development and industrialization project of long-acting microsphere preparation, goserelin acetate microspheres for injection, submitted by the Lizhu Group Party Committee and organized by the scientific research Party branch, won the first prize in the innovation group. Wang Yanqing, secretary of the Lizhu scientific research Party branch and deputy general manager of Lizhu Microsphere Company, presented the project and received the award at the award ceremony. The competition aims to enhance the organizational capacity of Party organizations, improve the level of innovation and entrepreneurship, create an atmosphere for the special zone's "second entrepreneurship", and contribute to the construction of the Guangdong-Hong Kong-Macao Greater Bay Area. The competition is divided into entrepreneurship and innovation groups, with three competition areas: Zhuhai, Chongqing, and Fuzhou. After three months of preliminary, semi-final, and final rounds, the research and development and industrialization project of long-acting microsphere preparation, goserelin acetate microspheres for injection, won the unanimous favor of the judges in all rounds with its advanced technology and the original intention of benefiting patients, winning the first prize in the innovation group. After receiving the award, Wang Yanqing, secretary of the Lizhu scientific research Party branch and deputy general manager of Lizhu Microsphere Company, delivered an acceptance speech, saying that he thanked the Zhuhai Municipal Committee Organization Department, the Zhuhai "Two New" Organization Party Working Committee, and the Zhuhai Xiangzhou District Committee and District Government for providing this platform to showcase innovative achievements, and thanked the Lizhu Group Party Committee for its strong support. Lizhu Group is a pharmaceutical enterprise that has grown up with the special zone. For more than 30 years, it has been driven by research and development innovation. The research and development and industrialization of long-acting microsphere preparation, goserelin acetate microspheres for injection, is another good product of Lizhu that benefits patients, and will also provide reference experience for domestic sustained-release technology, promoting the development of the domestic pharmaceutical industry.

Both "Jingxin" and "Tai Tai" brands have won the honor of "Shenzhen Old Brand"

Time Posted：2019-01-16 14:43

On January 14, 2019, the opening ceremony and awards ceremony of the 5th Shenzhen Merchants Global Conference, hosted by the Shenzhen Merchants Association and the Shenzhen Commercial Federation, and themed "Perfect Combination, Boundless Dapeng," was grandly held at the Shenzhen Poly Theater. This conference, in collaboration with Zhuhai, connected nine cities and two special administrative regions in the Guangdong-Hong Kong-Macao Greater Bay Area, focusing on discussions of Bay Area economic cooperation, corporate globalization, technological innovation, patent intellectual property rights, new economic models, and brand inheritance in the context of the current global economic situation, jointly planning the development of the Bay Area and discussing the global future. The conference attracted over 10,000 participants, including Shenzhen Municipal Party Committee Standing Committee Member and Minister of the United Front Work Department Lin Jie, Executive Vice Mayor of the Municipal Government Liu Qingsheng, Executive Vice Chairman of the Municipal People's Congress Standing Committee Luo Li; former Shenzhen Municipal Party Committee Secretary Li Youwei, former Municipal Government Mayor Yu Youjun, former Municipal Party Committee Vice Secretary Zhuang Lixiang, former Vice Chairman of the Municipal People's Congress Qiu Mei, former Vice Chairman of the Municipal Committee of the Chinese People's Political Consultative Conference Li Lianhe; Shenzhen Municipal Committee of the Chinese People's Political Consultative Conference Vice Chairman Xu Youjun, Zhuhai Municipal Party Committee Standing Committee Member and Vice Mayor Zhu Qingqiao, former President of the French National Assembly Claude Bartolone, and over 1,500 business representatives from across the country, including Shenzhen entrepreneurs Wang Shi, Li Dongsheng, Wang Chuanfu, Ma Weihua, Wang Wenyin, Mai Boliang, and Li Xiao, making it the largest, most influential, and most widely attended conference in history. At the 9th "Shenzhen Time-Honored Brands" Awards Ceremony held during the conference, the brands "Jingxin" and "Taital" under HealthGen Biotech Group were both honored. "Shenzhen Time-Honored Brands" represent a rigorous and inspiring business spirit, a shining golden signboard with a distinct Shenzhen cultural background and commercial connotation, and a precious resource and memory left behind from decades of Shenzhen's industrial and commercial development. HealthGen Biotech Group, after more than 20 years of development, has always taken the revitalization of China's pharmaceutical industry as its mission and aims to become one of China's best pharmaceutical companies. It adheres to the principle of making good medicine with care and steady operation, creating many high-quality products renowned worldwide. This is the fundamental reason why the brands under HealthGen Biotech Group have won the honor of "Shenzhen Time-Honored Brands." In the future, HealthGen Biotech Group will continue to uphold the spirit of craftsmanship, benefit society, and take professionalization, serialization, and humanization as its benchmarks, grasping the direction of the development of the greater health industry and creating more industry legends.

27 pharmaceutical companies were listed in the "2018 Guangdong Top 500 Enterprises in terms of Competitiveness"

Time Posted：2019-01-16 14:36

Seven pharmaceutical companies ranked among the top 100 in the overall list: Guangzhou Pharmaceutical Holdings Limited, Sinopharm Holding Co., Ltd., Shenzhen Haiwang Group Co., Ltd., Kangmei Pharmaceutical Co., Ltd., Shenzhen Haiwang Bioengineering Co., Ltd., Joincare Pharmaceutical Group Industry Co., Ltd., and Lizhu Pharmaceutical Group Co., Ltd. Guangzhou Pharmaceutical Holdings Limited ranked 25th. Guangzhou Pharmaceutical Holdings is one of the largest traditional Chinese medicine manufacturers in China. Traditional Chinese medicine is a key strength and industry characteristic for Guangzhou Pharmaceutical Holdings. The "fashionable traditional Chinese medicine" strategy directly drives the development of Guangzhou Pharmaceutical Holdings. Currently, market competition in the health industry is becoming increasingly fierce, and the industry is undergoing transformation. Chairman Li Chuyuan stated that Guangzhou Pharmaceutical must seize the opportunities of the new round of reform and opening up, strive to be a pioneer, build a world-class enterprise with unique industry characteristics and distinctive culture, and strive to enter the world's top 500 by 2020. Sinopharm Holding Co., Ltd. ranked 41st. Sinopharm Holding Co., Ltd. is a comprehensive pharmaceutical listed company integrating pharmaceutical R&D, pharmaceutical manufacturing, pharmaceutical distribution, and pharmaceutical logistics. It undertakes the task of national, provincial, and municipal government pharmaceutical reserves. Sinopharm's pharmaceutical distribution business ranks among the top in Guangdong and Guangxi provinces, ranking among the top 20 in China's pharmaceutical commerce. Its subsidiaries are located in Shenzhen, Guangzhou, Dongguan, Foshan, Zhanjiang, Meizhou, Zhaoqing, Huizhou, Nanning, Liuzhou, Jiangmen, Guilin, Yulin, and Baise, covering various business models such as hospital direct sales, commercial allocation, express delivery of pharmaceuticals, and terminal distribution. Shenzhen Haiwang Group Co., Ltd. ranked 50th. Haiwang Group is a large comprehensive pharmaceutical group company engaged in pharmaceutical manufacturing, commercial distribution, and retail chains. For many years, Haiwang has adhered to the pharmaceutical industry as its core and taken the revitalization of the national pharmaceutical industry as its mission. Its operating scale has continued to expand, forming three pillar industries: pharmaceutical manufacturing, pharmaceutical retail chains, and pharmaceutical commercial distribution. Kangmei Pharmaceutical Co., Ltd. ranked 55th. Kangmei Pharmaceutical is a large modern pharmaceutical enterprise and a national key high-tech enterprise, mainly engaged in the production of traditional Chinese medicine extracts, chemical raw materials, and preparations, integrating pharmaceutical production, R&D, and marketing of pharmaceuticals and medical devices. Recently, Kangmei Pharmaceutical encountered a setback. At the beginning of 2019, Kangmei Pharmaceutical experienced consecutive daily limit downs, and its market value evaporated by more than 100 billion yuan from its highest point. The future of Kangmei Pharmaceutical remains uncertain. Shenzhen Haiwang Bioengineering Co., Ltd. ranked 64th. Shenzhen Haiwang Bioengineering Co., Ltd. is a large comprehensive enterprise group integrating pharmaceutical product R&D, pharmaceutical manufacturing, pharmaceutical commercial distribution, and pharmaceutical retail chains. Haiwang Group's pharmaceutical product R&D, pharmaceutical manufacturing, and pharmaceutical commercial distribution are the businesses of Haiwang Bioengineering Co., Ltd., which was listed in 1998. For many years, the company has been based on the forefront of the biopharmaceutical industry, actively promoting technological innovation, and continuously expanding in the pharmaceutical and bioengineering industries, achieving rapid development. Joincare Pharmaceutical Group Industry Co., Ltd. ranked 89th. Recently, Joincare Pharmaceutical Group Industry Co., Ltd.'s wholly-owned subsidiary, Shenzhen Tai Tai Pharmaceutical Co., Ltd., won the 20th China Patent Excellence Award for its invention patent "A Traditional Chinese Medicine Preparation for the Treatment of Women's Menopausal Syndrome" (Patent No.: ZL01139059.X). This award fully demonstrates the company's strength in independent R&D and technological innovation, and also represents the company's high level of technology and intellectual property protection awareness. The company will continue to increase R&D investment and continuously enhance the market competitiveness of its products. Lizhu Pharmaceutical Group Co., Ltd. ranked 90th. As an important member of the pharmaceutical industry, judging from the current product structure, Lizhu Pharmaceutical Group Co., Ltd. still occupies a place in the huge pharmaceutical market. For example, the company's digestive drugs have huge growth potential, and microsphere drugs also have growth potential. Although Lizhu Pharmaceutical's stock price has been halved in the past 10 months, with the maximum drop reaching 62.3%, which is a relatively large drop in the pharmaceutical industry, it is believed that the company will also actively take measures to solve its development problems. Article link: China Pharmaceutical Network http://www.zyzhan.com/news/detail/73131.html

Announcement from Joincare Pharmaceutical Group Industry Co., Ltd. regarding winning the China Patent Excellence Award

Time Posted：2019-01-02 14:54

Stock Code: 600380 Stock Name: Health Yuan Announcement No.: 2018-129 Joincare Pharmaceutical Group Industry Co., Ltd. Announcement on Winning the China Patent Gold Award The board of directors and all directors of this company guarantee that the content of this announcement does not contain any false records, misleading statements or major omissions, and assume individual and joint responsibility for the authenticity, accuracy and completeness of its content. Recently, the State Intellectual Property Office issued the "Decision on Awarding the 20th China Patent Award" (Guo Zhi Fa Yun Zi [2018] No. 36), and the invention patent of Shenzhen Tai Tai Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Joincare Pharmaceutical Group Industry Co., Ltd. (hereinafter referred to as "the Company"), "A Traditional Chinese Medicine Preparation for the Treatment of Women's Menopausal Syndrome" (Patent No.: ZL01139059.X) won the 20th China Patent Gold Award. This award is an important award granted in accordance with the "China Patent Award Appraisal Measures", recommended by the intellectual property work management agencies of relevant departments of the State Council, local intellectual property offices, relevant national industry associations, and academicians of the Chinese Academy of Sciences and the Chinese Academy of Engineering, reviewed by the China Patent Award Appraisal Committee, and audited and awarded by the State Intellectual Property Office and the World Intellectual Property Organization. The award fully reflects the company's independent research and development and technological innovation capabilities, representing the company's high level of science and technology and intellectual property protection awareness. The company will continue to increase R&D investment and continuously enhance the market competitiveness of its products. This announcement.

Mr. Zhu Baoguo and Health Yuan respectively won the China Annual Economic Person Award and the China Poverty Alleviation Contribution Award

Time Posted：2018-12-22 15:00

On December 21, 2018, the "Creating the Future • 2018 China Economic Annual Summit and China Economic Figures Ceremony," jointly hosted by the Enterprise Management magazine and the Economy magazine, was grandly held in Beijing. Themed "Focusing on New Role Models, Discussing the New Economy," the summit selected outstanding enterprises and entrepreneurs from various sectors of the Chinese economy through processes such as institutional recommendations, enterprise applications, and expert evaluations. Mr. Zhu Baoguo and Joincare Pharmaceutical Group Industry Co., Ltd. (hereinafter referred to as "Health Yuan Group") stood out, winning the "China Annual Economic Figure" and "China Poverty Alleviation Contribution Award" respectively. This summit, themed "Focusing on New Role Models, Discussing the New Economy," invited people from all walks of life to participate in high-level forums, roundtable discussions, expert speeches, and entrepreneur speeches to foresee, grasp, and lead trends, explore new driving forces for enterprise development, promote the spirit of Chinese entrepreneurs, and use the power of role models to promote high-quality development of the Chinese economy, as a tribute to the 40th anniversary of China's reform and opening up! In conscientiously and thoroughly implementing the spirit of the 19th National Congress of the Communist Party of China and promoting the spirit of Chinese entrepreneurs, under the leadership of Mr. Zhu Baoguo, Health Yuan Group, mindful of its social responsibilities as a listed company, focused on people's livelihood, actively responded to the precision poverty alleviation policy, and gave full play to the role of listed companies in poverty alleviation. It not only launched large-scale charitable activities, but also radiated and drove impoverished households in Datong, Shanxi Province to achieve poverty alleviation in situ, adapting measures to local conditions to promote local industrial poverty alleviation—developing the Astragalus membranaceus industry, forming one of the pillar industries for local poverty alleviation and wealth creation; at the same time, it actively carried out medical and health poverty alleviation projects in Zhaotien District, Guangyuan City and Songpan County, Aba Tibetan and Qiang Autonomous Prefecture, Sichuan Province. Health Yuan Group will continue to uphold its altruistic heart, practice its corporate social responsibility, and offer health and warmth to those in need.